Question

In: Finance

Plato Pharmaceuticals Ltd. has invested $150,000 to date in developing a new type of insect repellent....

Plato Pharmaceuticals Ltd. has invested $150,000 to date in developing a new type of insect repellent. The repellent is now ready for production and sale, and the marketing manager estimates are found in the chart below.

Year

Bottles per year

Selling Price

Variable Cost

1

150,000

$6.00

$3.00

2

165,000

$6.00

$3.15

3

175,000

$6.95

$3.25

4

190,000

$6.95

$3.55

5

190,000

$7.95

$3.60

6

170,000

$7.95

$3.90

Fixed costs (excluding amortization) are expected to be $200,000 a year. The figure is made up of $160,000 additional fixed costs and $40,000 fixed costs relating to the existing business that will be apportioned to the new business.

In order to produce the repellent, machinery and equipment costing $520,000 will have to be purchased immediately. The estimated residual (salvage) value of this machinery and equipment in six years time is $100,000. The business calculates depreciation following CCA rules.

The business has a cost of capital of 12%. CCA 30% (50% rule applicable) of depreciation will be used, and taxes are paid at a rate of 40%.

Plato Pharmaceuticals Ltd. has invested $100,000 to date in developing a new type of insect repellent. The repellent is now ready for production and sale, and the marketing manager estimates that the product will sell 150,000 bottles a year over the next five years. The selling price of the insect repellent will be $6 a bottle and variable costs are estimated to be $3 a bottle. Fixed costs (excluding amortization) are expected to be $200,000 a year. The figure is made up of $160,000 additional fixed costs and $40,000 fixed costs relating to the existing business that will be apportioned to the new business.

In order to produce the repellent, machinery and equipment costing $520,000 will have to be purchased immediately. The estimated residual (salvage) value of this machinery and equipment in five years time is $100,000. The business calculates depreciation following CCA rules.

The business has a cost of capital of 12%. CCA 30% (50% rule applicable) of depreciation will be used, and taxes are paid at a rate of 40%.

Required:

1.Create a cash flow statement for the product for the next 6 years

2.Calculate the net present value of the product.

3.Perform a Payback analysis using NPV and one without using NPV

4.Calculate the internal rate of return for the product.

5.Undertake sensitivity analysis to show how much the following factors would have to change before the product ceased to be worthwhile.

The initial cost of machinery and equipment

Operating costs – Fixed

Operating costs - variable

Price per bottle of repellent

The residual value of the machinery and equipment

Solutions

Expert Solution

Profit & Loss 0 1 2 3 4 5 6
Revenue 900000 990000 1216250 1320500 1510500 1351500
Variable Expenses 450000 519750 568750 674500 684000 663000
Fixed Expenses 200000 200000 200000 200000 200000 200000
Gross Profit 250000 270250 447500 446000 626500 488500
Depreciation 78000 132600 92820 64974 45481.8 31837.26
PBT 172000 137650 354680 381026 581018.2 456662.7
Tax 68800 55060 141872 152410.4 232407.3 182665.1
PAT 103200 82590 212808 228615.6 348610.9 273997.6
Depreciation Calculation
Cost of Eqpmt 520000
Depreciation 78000 132600 92820 64974 45481.8 31837.26
1) Cash Flow Statement 0 1 2 3 4 5 6
Outflows
Initial Investment for Developing New Insect Repellant 150000
Machinery Purchase 520000 -100000
Tax 68800 55060 141872 152410.4 232407.3 182665.1
Total Outflows 670000 68800 55060 141872 152410.4 232407.3 82665.1
Inflows
PBT 172000 137650 354680 381026 581018.2 456662.7
Add Depreciation 78000 132600 92820 64974 45481.8 31837.26
Total Inflows 250000 270250 447500 446000 626500 488500
Net Inflows -670000 181200 215190 305628 293589.6 394092.7 405834.9
2) NPV of the product (@ 12% discount factor) 4,43,467 $
3) Payback Period = Period in which initial investment is recovered
Gross Profit 250000 270250 447500 446000 626500 488500
Tax 68800 55060 141872 152410.4 232407.3 182665.1
Net Cash Inflows 181200 215190 305628 293589.6 394092.7 305834.9
Cumulative Net cash Inflows 181200 396390 702018 995607.6 1389700 1695535
Payback Calculation 0 0 2.895238656 2.895239 2.895239 2.895239
Payback Period 2.89 years
4) IRR Calculation
Profit & Loss 0 1 2 3 4 5 6
Revenue 900000 990000 1216250 1320500 1510500 1351500
Variable Expenses 450000 519750 568750 674500 684000 663000
Fixed Expenses 160000 160000 160000 160000 160000 160000
Gross Profit 290000 310250 487500 486000 666500 528500
Depreciation 78000 132600 92820 64974 45481.8 31837.26
PBT 212000 177650 394680 421026 621018.2 496662.7
Tax 84800 71060 157872 168410.4 248407.3 198665.1
PAT 127200 106590 236808 252615.6 372610.9 297997.6
Here fixed expenses are considered on incremental basis i.e. only additional fixed cost = 160000
Cash Flow Statement 0 1 2 3 4 5 6
Outflows
Initial Investment for Developing New Insect Repellant 150000
Machinery Purchase 520000 -100000
Tax 84800 71060 157872 168410.4 248407.3 198665.1
Total Outflows 670000 84800 71060 157872 168410.4 248407.3 98665.1
Inflows
PBT 212000 177650 394680 421026 621018.2 496662.7
Add Depreciation 78000 132600 92820 64974 45481.8 31837.26
Total Inflows 290000 310250 487500 486000 666500 528500
Net Inflows -670000 205200 239190 329628 317589.6 418092.7 429834.9
IRR 35.5%

Related Solutions

Plato Pharmaceuticals Ltd. has invested $100,000 to date in developing a new type of insect repellent....
Plato Pharmaceuticals Ltd. has invested $100,000 to date in developing a new type of insect repellent. The repellent is now ready for production and sale, and the marketing manager estimates that the product will sell 150,000 bottles a year for the first two years, 170,000 for year three and 200,000 for the next two years. The selling price of the insect repellent will be $6.00 a bottle and the variable costs are estimated to be $3.00 a bottle for Year...
Plato Pharmaceuticals Ltd. has invested $100,000 to date in developing a new type of insect repellent....
Plato Pharmaceuticals Ltd. has invested $100,000 to date in developing a new type of insect repellent. The repellent is now ready for production and sale, and the marketing manager estimates that the product will sell 150,000 bottles a year for the first two years, 170,000 for year three and 200,000 for the next two years. The selling price of the insect repellent will be $6.00 a bottle and the variable costs are estimated to be $3.00 a bottle for Year...
4. You are visiting the rainforest, but unfortunately your insect repellent has run out. As a...
4. You are visiting the rainforest, but unfortunately your insect repellent has run out. As a result, at each second, a mosquito lands on your neck with probability 0.5. If one lands, with probability 0.2 it bites you, and with probability 0.8 it never bothers you, independently of other mosquitoes. a. What is the expected time between successive mosquito bites? What is the variance of the time between successive mosquito bites? b. In addition, a tick lands on your neck...
06. Testing a new insect repellent. (Adapted from McClave, Benson, & Sincich, 12th edition, page 556)....
06. Testing a new insect repellent. (Adapted from McClave, Benson, & Sincich, 12th edition, page 556). A study in the Journal of the American Mosquito Control Association (Mar. 1995) investigated whether a tent sprayed with a commercially available 1% permethrin formulation would protest people, both inside and outside the tent, against biting mosquitoes. Two canvas tents — one treated with permethrin, the other untreated — were position 25 meters apart on flat, dry ground in an area infested with mosquitoes....
The company that you manage has invested $5 million in developing a new product, but the...
The company that you manage has invested $5 million in developing a new product, but the development is not quite finished. At a recent meeting, your salespeople report that the introduction of competing products has reduced the expected sales of your new product to $3 million. If it would cost $1 million to finish development and make the product, you   go ahead and do so. The most you should pay to complete development is million.
Honey Ltd, a New Zealand company, has sold US$150,000 of products to the US, to receive...
Honey Ltd, a New Zealand company, has sold US$150,000 of products to the US, to receive cash exactly one month later. At the time of sale, the spot rate of exchange is US$0.55, that is, NZ$1 buys US$0.55. Honey Ltd wishes to hedge the currency risk associated with this transaction, so on the day of the sale, the company buys a put option – that is, it buys the right to sell US$150,000 at an exercise price of US$0.57 one...
New Dawn pharma is considering the acquisition of a small biotech company—Sunset Pharmaceuticals. Sunset is developing...
New Dawn pharma is considering the acquisition of a small biotech company—Sunset Pharmaceuticals. Sunset is developing a new drug that, if successful, would revolutionize the treatment of pancreatic and/or liver cancer. Sunset is about to start Phase I of the clinical testing for the new drug. New Dawn estimates that if they acquired Sunset the costs associated with Phase I testing would be around $60 million. They believe the probability of successful Phase I testing is 30%. Phase 2 testing...
New Dawn pharma is considering the acquisition of a small biotech company—Sunset Pharmaceuticals. Sunset is developing...
New Dawn pharma is considering the acquisition of a small biotech company—Sunset Pharmaceuticals. Sunset is developing a new drug that, if successful, would revolutionize the treatment of pancreatic and/or liver cancer. Sunset is about to start Phase I of the clinical testing for the new drug. New Dawn estimates that if they acquired Sunset the costs associated with Phase I testing would be around $60 million. They believe the probability of successful Phase I testing is 30%. Phase 2 testing...
New Dawn pharma is considering the acquisition of a small biotech company—Sunset Pharmaceuticals. Sunset is developing...
New Dawn pharma is considering the acquisition of a small biotech company—Sunset Pharmaceuticals. Sunset is developing a new drug that, if successful, would revolutionize the treatment of pancreatic and/or liver cancer. Sunset is about to start Phase I of the clinical testing for the new drug. New Dawn estimates that if they acquired Sunset the costs associated with Phase I testing would be around $60 million. They believe the probability of successful Phase I testing is 30%. Phase 2 testing...
SnapOn produces a variety of pharmaceuticals in large liquid batches. SnapOn business model to date has...
SnapOn produces a variety of pharmaceuticals in large liquid batches. SnapOn business model to date has been to sell the drugs in liquid form to other companies that convert the liquid drug into dosage form for sale to consumers. SnapOn’s reputation for quality and service depends on its unsurpassed capability to handle liquids safely and with minimal waste. The company’s marginal tax rate is 30% and its weighted average cost of capital is 13.86%. One of SnapOn’s processes involves consuming...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT